Physician

Wallace Cary Peterson, MD

According to 2025 Medicare claims, Wallace Peterson, MD (NPI: 1760472039) practices hematology/oncology in the Lincoln, NE market, with the plurality of this provider's patient population coming from Lancaster, NE. This provider's primary affiliated billing organization is CANCER PARTNERS OF NEBRASKA PC (NPI: 1437111408; TIN: 911862785) and primary practice location at 68516-5587. Peterson is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287) and Bryan Health Connect ACO, LLC (ACO ID: A4573), participating under the MSSP model.

Peterson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 897 traditional Medicare patients, billed 151,488 HCPCS/CPT codes, and received $2,672,052 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,551 prescription claims across 192 beneficiaries totaling $3,177,226 in drug costs, led by Revlimid (Lenalidomide). DME data shows 42 claims. Open Payments data shows 59 records totaling $1,010. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $8,095 to $6,222.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,145	183,527	$2,236,971
2016	1,050	153,830	$2,299,640
2017	1,164	155,659	$2,235,639
2018	983	146,714	$2,886,103
2019	1,137	214,929	$3,275,288
2020	1,103	211,889	$3,126,715
2021	1,122	198,455	$2,747,435
2022	1,037	202,436	$3,042,466
2023	1,017	177,252	$2,958,134
2024	897	151,488	$2,672,052

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	212	1,697	$1,887,846
2016	216	1,957	$1,847,896
2017	220	1,583	$1,829,739
2018	202	1,586	$2,137,412
2019	191	1,541	$2,172,047
2020	187	1,421	$1,958,848
2021	187	1,302	$1,422,549
2022	179	1,273	$1,512,850
2023	171	1,288	$1,512,241
2024	192	1,551	$3,177,226

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	146	$13,241
2016	54	221	$36,801
2017	N/R	71	$6,806
2018	N/R	90	$11,448
2019	N/R	61	$3,460
2020	N/R	68	$2,986
2021	N/R	115	$4,531
2022	11	95	$2,995
2023	11	18	$1,253
2024	16	42	$1,751

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	331	1,030	$86
80053	Blood test, comprehensive group of blood chemicals	463	905	$10
36415	Insertion of needle into vein for collection of blood sample	464	1,004	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	531	1,206	$8
83615	Lactate dehydrogenase (enzyme) level	358	674	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	70	1,960	$996,075
Jakafi	Ruxolitinib Phosphate	57	1,710	$758,245
Xtandi	Enzalutamide	13	570	$255,473
Lonsurf	Trifluridine/Tipiracil Hcl	13	364	$144,363
Imatinib Mesylate	Imatinib Mesylate	30	898	$21,515

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	16	26	$1,450
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,010	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wallace Cary Peterson, MD?

Tedicare shows public-source Medicare data for Wallace Cary Peterson, MD (NPI 1760472039), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wallace Cary Peterson, MD have ACO affiliation data?

Wallace Cary Peterson, MD is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287) and Bryan Health Connect ACO, LLC (MSSP, ACO ID A4573).

What billing organization is linked to Wallace Cary Peterson, MD?

Wallace Cary Peterson, MD is linked to CANCER PARTNERS OF NEBRASKA PC (billing NPI 1437111408) in the available physician profile data.

Does Wallace Cary Peterson, MD have Open Payments data?

Wallace Cary Peterson, MD has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.